Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at
- Reported record product revenue of
$11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growth - Closed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in January
- Acquired and relaunched ultra rare disease product Galzin®
- Licensed
U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company’s pediatric endocrinology pipeline - Announced positive pivotal clinical study results for ET-600; preparing for an
April 2025 NDA submission - Manufactured ET-400 launch inventory in preparation for a potential approval on its PDUFA goal date of
May 28 - Management to hold Investor Day conference call today at
10:00am ET to discuss its recent acquisitions and review its product portfolio, market opportunities, and 2025 and long-term financial outlook
“The fourth quarter of 2024 was the most transformational in Eton’s history. We closed the pivotal acquisition of Increlex, acquired another high-value rare disease product in Galzin, and boosted our product pipeline with the license of Amglidia and initiation of two exciting new internal development projects, ET-700 and ET-800. We completed all this while continuing to execute on our base business, delivering record product sales and our 16th straight quarter of sequential revenue growth,” said
“We are poised for an acceleration of growth in 2025. Increlex was relaunched in January with our now fully dedicated pediatric endocrinology sales force and is already adding new patients at a pace well ahead of our expectations. Galzin was relaunched in March with our newly deployed metabolic sales force and has been well received by the Wilson disease community. Launch inventory for ET-400 has been manufactured and our team stands ready to launch the product within days of its PDUFA goal date of
Fourth Quarter and Recent Business Highlights
Delivered 16th straight quarter of sequential growth in product sales. Eton reported fourth quarter 2024 net sales of
Relaunched Increlex, which is tracking ahead of expectations. Increlex is a highly durable, complex biologic used for the treatment of an ultra-rare pediatric endocrinology condition that is estimated to impact approximately 200 children in the
Awarded second patent for ET-400 and preparing for potential launch. During the fourth quarter, Eton was granted an additional patent for ET-400 by the United States Patent & Trademark Office (USPTO). The patent, which expires in 2043, covers hydrocortisone oral liquid formulations and is expected to be listed in the FDA’s Orange Book upon approval. The Company has successfully manufactured launch quantities for the product and its sales and promotional campaigns are ready to go live. If approved on its
Acquired and re-launched Galzin. In January, Eton added the ultra-rare disease commercial product Galzin to its metabolic portfolio. Seeing the need for improved patient experience, increased awareness, and broader access and affordability, the Company relaunched Galzin on
Announced positive pivotal study results for ET-600 and the issuance of a patent. ET-600 passed its pivotal bioequivalence study, successfully demonstrating pharmacokinetic equivalence to the reference product. In addition, the Company was issued a patent covering the product’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA’s Orange Book upon the product’s approval. Eton is preparing to submit an NDA for ET-600 in April, which could allow for approval in the first quarter of 2026.
Disclosed two new internal development programs, ET-700 and ET-800. The Company has two new, high-value product candidates under development internally. More details regarding these previously undisclosed programs will be shared during Eton’s Investor Day conference call.
Acquired
Fourth Quarter Financial Results
Net Revenue: Total net revenues for the fourth quarter of 2024 increased 59% to
Gross Profit: Gross profit for the fourth quarter of 2024 was
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2024 were
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2024 were
Net Loss: Net loss for the fourth quarter of 2024 was
Cash Position: As of
Conference Call and Webcast Information
As previously announced,
To participate, please click here to register. An archived webcast will be available on the Investors section of Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the
T: 212-452-2793
E: lwilson@insitecony.com
STATEMENTS OF OPERATIONS (In thousands, except per share amounts) |
|||||||||||||||||
| For the three months ended | For the years ended | ||||||||||||||||
| (Unaudited) | |||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenues: | |||||||||||||||||
| Licensing revenue | $ | — | $ | — | $ | 500 | $ | 5,500 | |||||||||
| Product sales and royalties, net | 11,647 | 7,313 | 38,511 | 26,142 | |||||||||||||
| Total net revenues | 11,647 | 7,313 | 39,011 | 31,642 | |||||||||||||
| Cost of sales: | |||||||||||||||||
| Licensing revenue | — | 1,000 | 270 | 1,000 | |||||||||||||
| Product sales and royalties | 5,171 | 2,683 | 15,330 | 9,581 | |||||||||||||
| Total cost of sales | 5,171 | 3,683 | 15,600 | 10,581 | |||||||||||||
| Gross profit | 6,476 | 3,630 | 23,411 | 21,061 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | (871 | ) | 1,047 | 3,255 | 3,322 | ||||||||||||
| General and administrative | 6,718 | 4,575 | 22,753 | 18,931 | |||||||||||||
| Total operating expenses | 5,847 | 5,622 | 26,008 | 22,253 | |||||||||||||
| Income (loss) from operations | 629 | (1,992 | ) | (2,597 | ) | (1,192 | ) | ||||||||||
| Other (expense) income: | |||||||||||||||||
| Interest and other (expense) income, net | (1,140 | ) | (17 | ) | (1,211 | ) | 503 | ||||||||||
| Loss before income tax expense | (511 | ) | (2,009 | ) | (3,808 | ) | (689 | ) | |||||||||
| Income tax expense | 87 | 247 | 15 | 247 | |||||||||||||
| Net loss | $ | (598 | ) | $ | (2,256 | ) | $ | (3,823 | ) | $ | (936 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.15 | ) | $ | (0.04 | ) | |||||
| Weighted average number of common shares outstanding, basic and diluted | 26,136 | 25,741 | 25,895 | 25,645 | |||||||||||||
BALANCE SHEETS (in thousands, except share and per share amounts) |
||||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 14,936 | $ | 21,388 | ||||
| Accounts receivable, net | 5,361 | 3,411 | ||||||
| Inventories, net | 15,232 | 911 | ||||||
| Prepaid expenses and other current assets | 5,492 | 1,129 | ||||||
| Total current assets | 41,021 | 26,839 | ||||||
| Property and equipment, net | 34 | 58 | ||||||
| Intangible assets, net | 34,881 | 4,739 | ||||||
| Operating lease right-of-use assets, net | 175 | 92 | ||||||
| Other long-term assets, net | 12 | 12 | ||||||
| Total assets | $ | 76,123 | $ | 31,740 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,167 | $ | 1,848 | ||||
| Current portion of long-term debt, net of discount | — | 5,380 | ||||||
| Accrued Medicaid rebates | 6,866 | 3,627 | ||||||
| Accrued liabilities | 8,914 | 5,386 | ||||||
| Total current liabilities | 19,947 | 16,241 | ||||||
| Long-term debt, net of discount and including accrued fees | 29,811 | — | ||||||
| Operating lease liabilities, net of current portion | 107 | 22 | ||||||
| Other long-term liabilities | 1,830 | — | ||||||
| Total liabilities | 51,695 | 16,263 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, |
27 | 26 | ||||||
| Additional paid-in capital | 132,294 | 119,521 | ||||||
| Accumulated deficit | (107,893 | ) | (104,070 | ) | ||||
| Total stockholders’ equity | 24,428 | 15,477 | ||||||
| Total liabilities and stockholders’ equity | $ | 76,123 | $ | 31,740 | ||||
STATEMENTS OF CASH FLOWS (In thousands) |
||||||||||||||||
| For the three months ended | For the years ended | |||||||||||||||
| (Unaudited) | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Cash flows from operating activities | ||||||||||||||||
| Net loss | $ | (598 | ) | $ | (2,256 | ) | $ | (3,823 | ) | $ | (936 | ) | ||||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||
| Stock-based compensation | 782 | 750 | 3,165 | 3,137 | ||||||||||||
| Depreciation and amortization | 355 | 325 | 1,146 | 901 | ||||||||||||
| Non-cash lease expense | 17 | 17 | 70 | 67 | ||||||||||||
| Debt discount amortization | 1,039 | 27 | 1,109 | 117 | ||||||||||||
| Changes in operating assets and liabilities, net of impact of product acquisitions: | — | — | ||||||||||||||
| Accounts receivable | (939 | ) | 84 | (3,118 | ) | (1,559 | ) | |||||||||
| Inventories | (34 | ) | 140 | (1,061 | ) | (354 | ) | |||||||||
| Prepaid expenses and other assets | (3,520 | ) | (655 | ) | (3,349 | ) | 94 | |||||||||
| Accounts payable | 1,482 | 105 | 2,318 | 53 | ||||||||||||
| Accrued Medicaid rebates | (1,181 | ) | 476 | 3,239 | 2,818 | |||||||||||
| Accrued liabilities | 2,043 | 1,374 | 1,484 | 2,477 | ||||||||||||
| Other non-current assets and liabilities | 38 | — | 38 | — | ||||||||||||
| Net cash from operating activities | (516 | ) | 387 | 1,218 | 6,815 | |||||||||||
| Cash from investing activities | ||||||||||||||||
| Purchases of property and equipment | (12 | ) | — | (26 | ) | — | ||||||||||
| Acquisition of business | (30,000 | ) | — | (30,000 | ) | — | ||||||||||
| Purchase of product licensing rights | (8,369 | ) | (775 | ) | (10,237 | ) | (775 | ) | ||||||||
| Net cash from investing activities | (38,381 | ) | (775 | ) | (40,263 | ) | (775 | ) | ||||||||
| Cash flows from financing activities | ||||||||||||||||
| Net proceeds from the issuance of long-term debt | 25,309 | — | 25,309 | — | ||||||||||||
| Repayment of long-term debt | — | (385 | ) | (1,155 | ) | (1,155 | ) | |||||||||
| Common stock issued in private placement offering | 7,000 | — | 7,000 | — | ||||||||||||
| Proceeds from stock option exercises | 1,015 | — | 1,191 | 148 | ||||||||||||
| Payment of tax withholding related to net share settlement of stock option exercises | — | — | — | (180 | ) | |||||||||||
| Employee stock purchase plan | 108 | 91 | 248 | 229 | ||||||||||||
| Stock warrant exercises | — | — | — | — | ||||||||||||
| Net cash from financing activities | 33,432 | (294 | ) | 32,593 | (958 | ) | ||||||||||
| Change in cash and cash equivalents | (5,465 | ) | (682 | ) | (6,452 | ) | 5,082 | |||||||||
| Cash and cash equivalents at beginning of period | 20,401 | 22,070 | 21,388 | 16,305 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 14,936 | $ | 21,388 | $ | 14,936 | $ | 21,388 | ||||||||
| Supplemental disclosures of cash flow information | ||||||||||||||||
| Cash paid for interest | $ | 140 | $ | 204 | $ | 665 | $ | 842 | ||||||||
| Cash paid for income taxes | $ | (99 | ) | $ | 247 | $ | 82 | $ | 247 | |||||||
| Supplemental disclosures of non-cash investing and financing activities: | ||||||||||||||||
| Debt issuance costs | $ | 386 | $ | — | $ | 386 | $ | — | ||||||||
| Fair value of warrants issued in connection with debt agreement | $ | — | $ | — | $ | 1,171 | $ | — | ||||||||
| Right-of-use assets obtained in exchange for lease liabilities | $ | 66 | $ | — | $ | 219 | $ | 29 | ||||||||
Source: Eton Pharmaceuticals